Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jun 7;207(6):1173–1182. doi: 10.1084/jem.20091318

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 Morita et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 3. — Reconstitution kinetics with CD150^high, CD150^med, and CD150^neg CD34⁻KSL cells. Each of a group of lethally irradiated mice received 10 CD150^high cells, 10 CD150^med cells, or 10 CD150^negCD34⁻KSL cells. (left) The change in the percentage of chimerism over time. Blood of recipient mice was analyzed 2, 3, 4, and 5 mo after transplantation. Each line shows a change in the percentage of chimerism from one recipient mouse. (right) The relative myeloid, B lymphoid, and T lymphoid lineage contributions in reconstituted donor-derived blood cells of individual recipient mice 4 mo after transplantation. Myeloid lineage represents 53.7 ± 27.2% (n = 19), 22 ± 21.8% (n = 19), and 13 ± 21.7% (n = 14; mean ± SD) after transplantation with CD150^high, CD150^med, and CD150^negCD34⁻KSL cells, respectively. B lymphoid lineage represents 38.2 ± 21.5% (n = 19), 56.2 ± 17.9% (n = 19), and 60.7 ± 21.5% (n = 14; mean ± SD) after transplantation with CD150^high, CD150^med, and CD150^negCD34⁻KSL cells, respectively. T lymphoid lineage represents 8 ± 8.4% (n = 19), 21.8 ± 9.4% (n = 19), and 26.3 ± 19.4% (n = 14; mean ± SD) after transplantation with CD150^high, CD150^med, and CD150^negCD34⁻KSL cells, respectively. The proportion of myeloid lineage reconstitution by CD150^highCD34⁻KSL cells was significantly greater than that of CD150^negCD34⁻KSL cells (P < 0.0001).